Professional Documents
Culture Documents
Virtual Vaccines Day 2020 Agenda V 14 PDF
Virtual Vaccines Day 2020 Agenda V 14 PDF
Agenda
Agenda
1
Vaccine Virtual Days
Agenda
Programme at-a-glance
Please click on the session title for more details.
A full listing of the Vaccine Virtual Days speakers can also be viewed here.
Please note that depending on your country regulations you may not be able to participate to each session.
2
Vaccine Virtual Days
Agenda
All sessions feature live translation and will be available in the following languages:
German (DE) Spanish (ES) French (FR) Italian (IT) Portuguese (PT)
Live sessions will also be recorded and made available on-demand starting as from July 1st, 2020. On-demand
offering will include the above language versions.
Paediatricians
General practitioners
Vaccinators
Vaccine developers
Immunologists
Pulmonologists
3
Vaccine Virtual Days
Agenda
Day 1, 29 June
13:00–16:20 CEST (GMT+2 Belgium)
Event opening
13:00–13:15 Introduction by Peter Piot (UK)
4
Vaccine Virtual Days
Agenda
Day 1, 29 June
16:35–18:15 CEST (GMT+2 Belgium)
Nonspecific effects of
16:35–16:45 Introduction Marco Sáfadi (Brazil)
vaccines
Trained immunity: a
16:45–17:00 memory for innate host Presentation Mihai Netea (Netherlands)
defense
Impact of influenza
vaccination in other
17:30–17:45 Presentation Albert Osterhaus (Germany)
respiratory virus
infections
Moderator: Marco Sáfadi (Brazil)
Speakers:
17:45–18:15 Discussion Q&A Mihai Netea (Netherlands)
Nigel Curtis (Australia) - TBC
Federico Martinón Torres (Spain)
Albert Osterhaus (Germany)
18:15–18:30 Session break
5
Vaccine Virtual Days
Agenda
Day 1, 29 June
18:30–20:15 CEST (GMT+2 Belgium)
Speakers:
20:05–20:15 Discussion Q&A
Peter Hotez (USA)
Paul-Henri Lambert (Switzerland)
Miriam Sturkenboom (Netherlands)
20:15–20:30 Sub-session break
6
Vaccine Virtual Days
Agenda
Day 1, 29 June
20:30–21:00 CEST (GMT+2 Belgium)
7
Vaccine Virtual Days
Agenda
Day 2, 30 June
14:00–16:15 CEST (GMT+2 Belgium)
Event opening
14:00–14:15 Introduction by Peter Piot (UK)
Pathogenesis of COVID-19:
14:35–14:50 Presentation Malik Peiris (Hong Kong)
is it something unique?
Moderator:
Philippe Buchy (GSK - SG)
The known unknown and
15:45–16:15 Round table
the unknown known Speakers:
Malik Peiris (Hong Kong)
David Hui (Hong Kong)
8
Vaccine Virtual Days
Agenda
Day 2, 30 June
16:30–17:45 CEST (GMT+2 Belgium)
• Preclinical/clinical/post
marketing
Overview general vaccine Bart Haagmans (Netherlands)
16:35–16:55 • Regulatory considerations in
development Philip Krause (USA)
evaluating vaccine safety and
efficacy
9
Vaccine Virtual Days
Agenda
Day 2, 30 June
18:00–19:10 CEST (GMT+2 Belgium)
10
Vaccine Virtual Days
Agenda
Day 2, 30 June
19:25–22:15 CEST (GMT+2 Belgium)
19:30–19:45 Outline of the AMR problem Presentation and Q&A Jim O’Neill (UK)
Role of biological
20:15–20:30 Presentation and Q&A Paul Stickings (UK)
standards in reducing AMR
11
Vaccine Virtual Days
Agenda
General immune response to This short animation recaps how our innate and adaptive
Video (approx. 2 min)
infection immune systems each respond to a pathogen invasion
12
Vaccine Virtual Days
Agenda
Scientific Committee
Speakers
Ashley Birkett Director of PATH’s Malaria Vaccine Initiative (MVI), Washington, DC USA
13
Vaccine Virtual Days
Agenda
14
Vaccine Virtual Days
Agenda
Rino Rappuoli Chief Scientist and Head of External R&D, GSK Vaccines Italy
Thomas Breuer Senior Vice President, Chief Medical Officer, GSK Vaccines Belgium
Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency
for Medicines and Health Products adversedrugreactions@af mps.be or via the ‘yellow card’ available on www.fagg-afmps.be or
to GlaxoSmithKline Pharmaceuticals s.a./n.v. 010/ 85 85 00.
For other countries, to report adverse events, details can be found at: https://www.gsk.com/en-gb/contact-us/report-a-possible-
side-effect/
15